Therapeutic goods regulation
The regulatory framework reflects and upholds the Australian community’s expectations around the safety and quality of therapeutic goods on the market.
Latest articles
- TGA consults on potential nicotine vaping product regulatory reformsThe TGA is seeking public comment on potential reforms to the regulation of nicotine vaping products in Australia.
- A warning that advertising Ozempic (semaglutide) is prohibitedA warning to social media influencers and advertisers not to advertise this prescription medicine.
- Post-market review of spinal cord stimulation (SCS) devicesFind out more about the post market review the TGA is undertaking on spinal cord stimulators (SCS).
Latest publications
- Pharmacovigilance Inspection Program metrics report: Jan - Dec 2021The TGA Pharmacovigilance Inspection Program (PVIP) metrics report for 2021 is now available.
- Notice of interim decisions on proposed amendments to the Poisons Standard – ACMS #38, ACCS #34, Joint ACMS-ACCS #31 – June 2022Interim decisions and invitation for further comment. Closing date: 24 November 2022
- Notice of interim decisions on proposed amendments to the Poisons Standard - ACMS #37 ACCS #33 Joint ACMS-ACCS #30 - March 2022Interim decisions and invitation for further comment. Closing date: 15 September 2022